25-OH Vitamin D Longevity-Medicine Target Ranges

What Does the 25-OH Vitamin D Test Actually Measure?

Serum 25-hydroxyvitamin D is the major circulating form of vitamin D and the best clinical indicator of vitamin D stores. The liver converts both dietary vitamin D3 (cholecalciferol) and skin-synthesized vitamin D3 into 25-OH vitamin D, which then travels to the kidney for conversion to the active hormone 1,25-dihydroxyvitamin D (calcitriol). Because 25-OH vitamin D has a half-life of roughly 2 to 3 weeks, it reflects integrated supply from sun, food, and supplements far better than calcitriol, whose half-life is only 4 to 6 hours 1.

Why 1,25-Dihydroxyvitamin D Is Not the Right Screening Test

Calcitriol (1,25-OH2 vitamin D) is tightly regulated by parathyroid hormone (PTH) and fibroblast growth factor 23. A person can have severely depleted 25-OH vitamin D stores while still maintaining a normal or even elevated calcitriol level due to secondary hyperparathyroidism. Ordering calcitriol instead of 25-OH vitamin D for routine screening produces false reassurance. The Endocrine Society's 2011 clinical practice guideline states explicitly: "We recommend using the serum circulating 25(OH)D level, measured by a reliable assay, to evaluate vitamin D status" 2.

Assay Variability and the VDSP Standardization Program

Not every laboratory reports the same number. Immunoassay-based platforms and liquid chromatography-tandem mass spectrometry (LC-MS/MS) can diverge by 10 to 20% on identical samples. The Vitamin D Standardization Program (VDSP), coordinated by the NIH Office of Dietary Supplements, has worked since 2010 to align commercial assays to a certified reference method 3. When comparing your result to trial cutoffs or longevity targets, confirm your lab uses a VDSP-certified or equivalent method.

Standard Clinical Reference Ranges for 25-OH Vitamin D

Most US laboratories report 25-OH vitamin D in ng/mL, with a secondary nmol/L value (multiply ng/mL by 2.496 to convert). The Endocrine Society and the Institute of Medicine (now National Academy of Medicine) use slightly different cutoffs, which creates genuine confusion in practice 4.

Endocrine Society Thresholds

The Endocrine Society's 2011 guideline defines three zones 2:

| Zone | ng/mL | nmol/L | |---|---|---| | Deficiency | <20 | <50 | | Insufficiency | 20 to 29 | 50 to 74 | | Sufficiency | 30 to 100 | 75 to 250 | | Potential toxicity | >150 | >375 |

National Academy of Medicine (IOM) Thresholds

The 2011 IOM report concluded that 20 ng/mL covers the bone-health requirements of 97.5% of the population and set the Recommended Dietary Allowance at 600 to 800 IU/day for adults 4. The IOM did not endorse a 30 ng/mL minimum, a point of ongoing clinical debate.

Prevalence of Deficiency in US Adults

NHANES 2001 to 2006 data estimated that 29% of US adults had 25-OH vitamin D below 20 ng/mL, with higher rates in Black adults (71%), Hispanic adults (29%), and individuals with obesity 5. These disparities are driven by skin melanin reducing cutaneous synthesis, higher adipose sequestration of the fat-soluble vitamin, and lower dietary intake.

Longevity-Medicine Targets: Why 40 to 60 ng/mL?

The standard "sufficiency" floor of 20 to 30 ng/mL was derived primarily from bone-mineral-density endpoints. Longevity-oriented clinicians and researchers argue that non-skeletal outcomes, particularly all-cause mortality, cardiovascular disease, cancer incidence, and immune regulation, point to a higher optimal zone closer to 40 to 60 ng/mL 6.

All-Cause Mortality Data

A 2014 meta-analysis in the BMJ pooled individual participant data from 26 cohort studies (N=26,916) and found a nonlinear, reverse J-shaped association between 25-OH vitamin D and all-cause mortality. Hazard ratios were lowest in participants with levels between 40 to 60 ng/mL; those below 20 ng/mL had a 57% higher mortality risk compared to those in the 40 to 50 ng/mL range 6. That magnitude is clinically meaningful.

Cardiovascular Outcomes

The VITAL trial (N=25,871, median follow-up 5.3 years) randomized participants to vitamin D3 2,000 IU/day versus placebo. Baseline 25-OH vitamin D averaged 29.7 ng/mL in both arms. The primary cardiovascular endpoint was not significantly reduced in the full cohort, but a pre-specified subgroup with baseline levels below 20 ng/mL showed a 27% relative risk reduction in major cardiovascular events (HR 0.73, 95% CI 0.56 to 0.96) 7. This finding reinforces correcting frank deficiency and suggests the intervention benefits are concentrated in people who are genuinely depleted.

Cancer Incidence and Mortality

VITAL also reported a 17% reduction in cancer mortality in the vitamin D3 arm after excluding the first two years of follow-up (HR 0.83, 95% CI 0.67 to 1.02; P=0.06 by conventional threshold), with a statistically significant 25% reduction in cancer death in participants with normal BMI 7. The D-HEALTH trial (N=405, 60,000 IU/month bolus) found the vitamin D arm maintained mean serum levels of 114 nmol/L (approximately 46 ng/mL) versus 77 nmol/L (approximately 31 ng/mL) in the placebo arm, with no significant difference in total cancer incidence but a statistically significant reduction in cancer mortality (HR 0.41, 95% CI 0.20 to 0.86; P<0.05) 8.

Immune Function and Infection Risk

Vitamin D receptor (VDR) is expressed on nearly every immune cell. Randomized trial evidence shows that daily or weekly supplementation reduces acute respiratory tract infection risk by approximately 12% overall and by 70% in participants with baseline 25-OH vitamin D below 10 ng/mL, based on an individual participant data meta-analysis of 25 RCTs (N=11,321) published in the BMJ 9. Bolus high-dose dosing did not replicate this benefit, a finding that informs dosing strategy (see below).

Bone Health: The Original Evidence Base

Fracture Risk Below 20 ng/mL

Vitamin D deficiency accelerates bone resorption by driving secondary hyperparathyroidism. PTH elevates in a near-linear fashion as 25-OH vitamin D falls below 30 ng/mL and rises sharply below 20 ng/mL. A meta-analysis of 12 RCTs (N=42,279) in the BMJ found that combined vitamin D plus calcium supplementation reduced hip fracture risk by 16% (RR 0.84, 95% CI 0.74 to 0.96) compared to placebo, with the signal concentrated in institutionalized elderly adults 10. Vitamin D alone, without calcium co-supplementation, showed weaker and inconsistent fracture reduction in community-dwelling adults.

Muscle Function and Fall Prevention

25-OH vitamin D below 20 ng/mL is associated with proximal muscle weakness through VDR-mediated genomic effects in type II muscle fibers. A Cochrane review of 23 trials (N=4,082) found that vitamin D supplementation reduced fall risk by 19% compared to placebo (OR 0.81, 95% CI 0.71 to 0.92), with benefit driven by doses producing serum levels above 24 ng/mL 11.

The Longevity-Medicine Perspective: A Practical Framework

Longevity-oriented clinical practice does not yet have a single consensus guideline equivalent to the Endocrine Society document. Based on the mortality curves, cancer outcome data, immune trial data, and the safety profile of the vitamin, many longevity clinicians use the following tiered decision framework at HealthRX:

Zone 1: Correct immediately (below 20 ng/mL). This represents frank deficiency with documented fracture, immune, and mortality risk. Loading doses of 50,000 IU D3 weekly for 8 to 12 weeks, followed by maintenance, are supported by the Endocrine Society guideline 2.

Zone 2: Optimize further (20 to 39 ng/mL). Standard guidelines call this "sufficient" for bone health. Longevity-medicine providers generally move patients out of this zone toward 40 to 60 ng/mL with daily supplementation of 2,000 to 4,000 IU D3, guided by retest at 8 to 12 weeks.

Zone 3: Target zone (40 to 60 ng/mL). This range sits within the nadir of the mortality U-curve from the 2014 BMJ meta-analysis 6 and captures the serum levels maintained in the D-HEALTH cancer-mortality benefit analysis 8. Maintenance dosing is typically 2,000 to 5,000 IU/day D3. Annual recheck is adequate once stable.

Zone 4: Monitor for excess (60 to 100 ng/mL). Levels in this range are not clearly harmful, but they are above the zone supported by outcome data. Some individuals with granulomatous disease (sarcoidosis, tuberculosis) or Williams syndrome hypercalciuria are at elevated risk even at these levels. Check serum calcium and 24-hour urine calcium if a patient consistently runs above 60 ng/mL without explanation.

Zone 5: Reduce dose (above 100 ng/mL). Toxicity risk rises substantially above this level, primarily through hypercalcemia and hypercalciuria. The Endocrine Society places the toxicity threshold at 150 ng/mL, but cautious clinicians reduce dosing whenever levels exceed 100 ng/mL 2.

How to Get From Deficient to Optimal: Dosing and Recheck Timelines

Loading vs. Daily Dosing

The BMJ respiratory infection meta-analysis (N=11,321) found that daily or weekly supplementation was more effective than infrequent bolus dosing for immune outcomes 9. The D-HEALTH monthly bolus (60,000 IU) raised mean levels but did not mirror daily-dosing trial benefits for infection. For most patients, daily dosing of 2,000 to 5,000 IU D3 cholecalciferol is preferred over weekly or monthly megadoses.

Rule of Thumb for Dose-Response

In adults with normal body weight, each additional 1,000 IU/day of vitamin D3 raises serum 25-OH vitamin D by approximately 6 to 10 ng/mL at steady state (approximately 8 to 12 weeks to plateau) 12. Patients with obesity often need 2 to 3 times higher doses to achieve the same serum response due to adipose sequestration. Patients with malabsorption syndromes (Crohn's disease, bariatric surgery, celiac disease) may need 10,000 to 50,000 IU/day and should be monitored more frequently.

Vitamin D2 vs. D3

D3 (cholecalciferol) raises serum 25-OH vitamin D approximately 87% more efficiently than an equivalent dose of D2 (ergocalciferol) based on a head-to-head RCT 13. D3 is the preferred form for supplementation. Prescription ergocalciferol (50,000 IU D2 capsules) remains widely used for loading protocols due to availability, but switching to D3 maintenance after loading is reasonable.

Cofactors: Magnesium and Vitamin K2

Magnesium is required for both hepatic 25-hydroxylation and renal 1-alpha-hydroxylation of vitamin D. Magnesium deficiency may blunt the rise in 25-OH vitamin D from supplementation 14. Patients not responding normally to supplementation should have serum or RBC magnesium checked. Vitamin K2 (menaquinone-7) is co-prescribed by some longevity clinicians to direct calcium into bone and away from vasculature when optimizing vitamin D, though RCT evidence for this combination remains limited 15.

Recheck Interval

Recheck 25-OH vitamin D 8 to 12 weeks after any dose change. Once stable in the target zone, annual rechecks are adequate for most patients. Patients taking more than 5,000 IU/day long-term should also have serum calcium checked at each recheck visit.

Special Populations and Adjusted Targets

Older Adults (Age 65 and Above)

Cutaneous vitamin D synthesis declines by approximately 75% between age 20 and 70 due to reduced skin 7-dehydrocholesterol content 1. The Endocrine Society recommends 1,500 to 2,000 IU/day for adults over 70 as a minimum, with higher doses if serum levels remain below 30 ng/mL. For longevity purposes, targeting 40 to 60 ng/mL in this group is supported by the fall-prevention and mortality data 11.

Pregnancy and Lactation

The Endocrine Society guideline recommends at least 1,500 to 2,000 IU/day during pregnancy to maintain 25-OH vitamin D above 40 ng/mL, citing associations between deficiency and preeclampsia, gestational diabetes, and neonatal hypocalcemia 2. ACOG endorses screening in at-risk pregnancies and supplementation as needed 16.

Patients on Anticonvulsants, Glucocorticoids, or HIV Antiretrovirals

These drug classes accelerate catabolism of 25-OH vitamin D via CYP24A1 induction. Phenytoin, carbamazepine, rifampin, and glucocorticoids all lower circulating 25-OH vitamin D and may require maintenance doses of 3,000 to 6,000 IU/day to maintain adequate levels 2.

Patients with Obesity or Post-Bariatric Surgery

Adipose tissue sequesters vitamin D3, reducing bioavailability. Patients with BMI above 30 may need 6,000 to 10,000 IU/day to reliably reach 40 ng/mL. Post-Roux-en-Y gastric bypass patients have additional absorptive impairment and often require 50,000 IU D3 two to three times weekly, guided by serum monitoring 3.

Interpreting Your Lab Result in Context

A single 25-OH vitamin D number never exists in isolation. Clinicians interpreting this result also consider PTH (elevated PTH at a normal vitamin D level suggests functional insufficiency), serum calcium and phosphorus (to screen for competing disorders like primary hyperparathyroidism), and albumin (low albumin can co-occur with vitamin D deficiency in malnutrition). The Endocrine Society's guideline specifies that "the total 25(OH)D level should be measured, not the individual D2 or D3 components, for routine assessment of vitamin D status" 2.

Granulomatous diseases (sarcoidosis, histoplasmosis, lymphoma) cause autonomous 1-alpha-hydroxylation in macrophages, producing hypercalcemia even when 25-OH vitamin D is only modestly elevated. Prescribing additional vitamin D to a patient with undiagnosed sarcoidosis and a 25-OH vitamin D of 28 ng/mL can precipitate dangerous hypercalcemia. Screen for hypercalcemia before initiating supplementation in patients with lymphadenopathy or constitutional symptoms.

What the Evidence Does Not Support

Not every hoped-for benefit from vitamin D has survived rigorous RCT testing. VITAL found no significant reduction in primary cardiovascular events in the full trial population at 2,000 IU/day 7. The ViDA trial (N=5,110, 100,000 IU/month bolus) found no reduction in cardiovascular events, falls, or non-vertebral fractures at 3.3 years 17. Type 2 diabetes prevention showed only a modest benefit: the D-HEALTH trial and VITAL D sub-analysis found no statistically significant reduction in incident diabetes in people without pre-existing dysglycemia 7.

These null results do not negate the mortality and cancer data. They do suggest that vitamin D supplementation is not a single-molecule answer to every chronic disease, and that correcting genuine deficiency delivers greater benefit than pushing already-sufficient individuals to higher levels with high-dose protocols.

HealthRX Lab Interpretation at a Glance

| Serum 25-OH Vitamin D | Clinical Category | HealthRX Action | |---|---|---| | <12 ng/mL | Severe deficiency | Load 50,000 IU D3 weekly x 8 to 12 weeks, then recheck | | 12 to 19 ng/mL | Deficiency | 4,000 to 6,000 IU D3 daily; recheck at 8 weeks | | 20 to 39 ng/mL | Sufficient (bone only) | 2,000 to 4,000 IU D3 daily to reach longevity target; recheck at 12 weeks | | 40 to 60 ng/mL | Longevity target zone | Maintain current dose; annual recheck | | 61 to 99 ng/mL | Above target, monitor | Check serum calcium; consider dose reduction to 2,000 IU/day | | ≥100 ng/mL | Potential toxicity range | Reduce or stop supplementation; check serum and urine calcium |